We are on a global mission to establish gene therapy as a new standard of care for highly prevalent ocular diseases.
Gene Therapy β’ Biotechnology β’ Rare Diseases β’ Ophthalmology β’ Retina
51 - 200
π° $217M Post-IPO Equity on 2020-08
October 12
51 - 200
Manager of Clinical Supply Chain at Adverum, a gene therapy company.
πΊπΈ United States β Remote
π΅ $120k - $140k / year
π° $217M Post-IPO Equity on 2020-08
β° Full Time
π‘ Mid-level
π Senior
π Supply Chain
π½ H1B Visa Sponsor